

09-J9000-01

Reviewed: 11/12/25

Revised: 01/01/26

Preferred Agents and Drug List

Rheumatoid Disorders

Disease State	Step 1a	Step 1b	Step 2	Step 3a	Step 3b	Step 3c
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Ankylosing Spondylitis (AS)	SC: adalimumab product(s)**, Cosentyx, Enbrel	Oral: Rinvoq, Xeljanz, Xeljanz XR	N/A	SC: Bimzelx, Cimzia, Simponi, Taltz	N/A	N/A
Nonradiographic Axial Spondyloarthritis (nr-axSpA)	SC: Cimzia, Cosentyx	Oral: Rinvoq	N/A	SC: Bimzelx, Taltz	N/A	N/A
Polyarticular Juvenile Idiopathic Arthritis (PJIA)	SC: adalimumab product(s)**, Enbrel	Oral: Rinvoq, Rinvoq LQ, Xeljanz	SC: Tyenne (an adalimumab product** is a required Step 1 agent)	SC: Cimzia	SC: Actemra (an adalimumab product** AND Tyenne are required Step 1 agents), Orencia	SC: Kevzara
Psoriatic Arthritis (PsA)	SC: adalimumab product(s)**, Cosentyx, Enbrel, Skyrizi, Tremfya, ustekinumab product(s)†† Oral: Otezla, Otezla XR	Oral: Rinvoq, Rinvoq LQ, Xeljanz, Xeljanz XR	N/A	SC: Bimzelx, Cimzia, Orencia, Simponi, Taltz	N/A	N/A
Rheumatoid Arthritis (RA)	SC: adalimumab product(s)**, Enbrel	Oral: Rinvoq, Xeljanz, Xeljanz XR	SC: Tyenne (an adalimumab product** is a required Step 1 agent)	SC: Cimzia, Kevzara, Orencia, Simponi Oral: Olumiant	SC: Actemra (an adalimumab product** AND Tyenne are required Step 1 agents)	SC: Kineret

Systemic Juvenile Idiopathic Arthritis (SJIA)	SC: Tyenne	N/A	SC: Actemra	N/A	N/A	N/A
--	-------------------	-----	--------------------	-----	-----	-----

Dermatological Disorders

Disease State	Step 1a	Step 1b	Step 2	Step 3a	Step 3b	Step 3c
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Hidradenitis Suppurativa (HS)	SC: adalimumab product(s)**, Cosentyx	N/A	N/A	SC: Bimzelx	N/A	N/A
Psoriasis (PS)	SC: adalimumab product(s)**, Cosentyx, Enbrel, Skyrizi, Tremfya, ustekinumab product(s)†† Oral: Otezla, Otezla XR, Sotyktu	N/A	N/A	SC: Bimzelx, Cimzia	N/A	SC: Siliq, Taltz

Inflammatory Bowel Disease

Disease State	Step 1a	Step 1b	Step 2	Step 3a	Step 3b	Step 3c
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Crohn's Disease (CD)	SC: adalimumab product(s)**, Entyvio, Skyrizi, Tremfya, ustekinumab product(s)††	N/A	SC: Omvoh Oral: Rinvoq	SC: Cimzia, Zymfentra	N/A	N/A

Ulcerative Colitis (UC)	SC: adalimumab product(s)**, Entyvio, Skyrizi, Tremfya, ustekinumab product(s)††	Oral: Xeljanz, Xeljanz XR	SC: Omvoh, Simponi Oral: Rinvoq	SC: Zymfentra Oral: Zeposia	N/A	Oral: Velsipity
--------------------------------	---	-------------------------------------	---	--	-----	------------------------

Other

Disease State	Step 1a	Step 1b	Step 2	Step 3a	Step 3b	Step 3c
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Giant Cell Arteritis (GCA)	SC: Tyenne Oral: Rinvoq	N/A	SC: Actemra (Tyenne is a required Step 1 agent)	N/A	N/A	N/A
Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)	SC: Tyenne	N/A	SC: Actemra	N/A	N/A	N/A
Uveitis	SC: adalimumab product(s)**	N/A	N/A	N/A	N/A	N/A

Indications Without Prerequisite Biologic Immunomodulators Required

Disease State	Step 1a	Step 1b	Step 2	Step 3a	Step 3b	Step 3c
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Alopecia Areata (AA) Atopic Dermatitis (AD) Deficiency of IL-1 Receptor Antagonist (DIRA) Enthesitis Related Arthritis (ERA) Juvenile Psoriatic	N/A	N/A	N/A	N/A	N/A	N/A

Arthritis (JPsA) Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Polymyalgia Rheumatica (PMR)						
---	--	--	--	--	--	--

**Allowable preferred adalimumab product(s): Adalimumab-aaty, Adalimumab-adaz, Hadlima, Humira, Simlandi

††Allowable preferred ustekinumab product(s): Stelara, Selarsdi, Steqeyma, Yesintek

Note: For Xeljanz products (Xeljanz and Xeljanz XR), Otezla products (Otezla and Otezla XR), and Rinvoq products (Rinvoq and Rinvoq LQ), a trial of either or both dosage forms collectively counts as **ONE** product.

UPDATE INFORMATION:

01/01/25	New document.
04/01/25	Revision. Omvoh added as a Step 2 agent for CD. Cimzia moved from a Step 3c agent to a Step 3a agent for PJIA. Cimzia for CD no longer always requires an adalimumab product as a required Step 1 agent.
05/15/25	Revision. Tremfya added as a Step 1a agent for CD.
07/01/25	Revision. The biosimilars of Selarsdi, Steqeyma, and Yesintek added among the preferred self-administered ustekinumab products that also still includes Stelara. The table now only references “ustekinumab product(s)”. Rinvoq added as a Step 1a agent for GCA. For Actemra SC, Tyenne SC is the required Step 1 agent for GCA.
01/01/26	Review and revision. Bimzelx moved from a Step 3c agent to a Step 3a agent for all FDA-approved indications. Otezla XR added as a step 1a agent at parity with Otezla. Rinvoq moved from a Step 1b agent to a Step 2 agent for the CD and UC indications.